Myasthenia Gravis Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Myasthenia Gravis Market to 2027 - Global Analysis and Forecasts By Treatment (Drug treatment, Rapid immunotherapies)

Report Code: TIPRE00005412 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Myasthenia Gravis is an autoimmune and neuromuscular disorder that results into weakness of muscles, characterized by fatigue and weakness. The main muscles impacted by this are the muscles that monitor swallowing and breathing, eye movement, eye lids, shoulder and facial muscles.

MARKET DYNAMICS
The Myasthenia Gravis market is anticipated to grow in the forecast, owing to the factors such as rising healthcare expenditure, improving healthcare infrastructure, growing occurrence of autoimmune disorders, and massive investments. Nevertheless, high cost of treatment and limited FDA-approved drugs are expected to restrict the market growth during the forecast period.

MARKET SCOPE
The "Global Myasthenia Gravis Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Myasthenia Gravis market with detailed market segmentation by Drugs and geography. The global Myasthenia Gravis market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Myasthenia Gravis market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Myasthenia Gravis market is segmented on the basis of treatment. Based on treatment the market is segmented into drug treatment and rapid immunotherapies. Drug treatment is further sub segmented into Cholinesterase Inhibitors, Monoclonal Antibodies, and Chronic Immunomodulators. Rapid immunotherapies is further sub segmented into Plasmapheresis, Intravenous Immunoglobulin (IVlg), and Thymectomy.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Myasthenia Gravis market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Myasthenia Gravis market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Myasthenia Gravis market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Myasthenia Gravis market in these regions.

MARKET PLAYERS
The reports cover key developments in the Myasthenia Gravis market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Myasthenia Gravis market are anticipated to lucrative growth opportunities in the future with the rising demand for Myasthenia Gravis market in the global market. Below mentioned is the list of few companies engaged in the Myasthenia Gravis market.

The report also includes the profiles of Myasthenia Gravis market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Novartis AG
  • NIHON PHARMACEUTICAL CO., LTD
  • Grifols, S.A.
  • Bausch Health
  • Alexion
  • F. Hoffmann-La Roche Ltd
  • Curavac
  • Bristol-Myers Squibb Company
  • Ra Pharmaceuticals, Inc
  • argenx
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Myasthenia Gravis Market - By Treatment
1.3.2 Myasthenia Gravis Market - By Region
1.3.2.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. MYASTHENIA GRAVIS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MYASTHENIA GRAVIS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. MYASTHENIA GRAVIS MARKET - GLOBAL MARKET ANALYSIS
6.1. MYASTHENIA GRAVIS - GLOBAL MARKET OVERVIEW
6.2. MYASTHENIA GRAVIS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. MYASTHENIA GRAVIS MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT
7.1. OVERVIEW
7.2. TREATMENT MARKET FORECASTS AND ANALYSIS
7.3. DRUG TREATMENT
7.3.1. Overview
7.3.2. Drug treatment Market Forecast and Analysis
7.3.3. Cholinesterase Inhibitors Market
7.3.3.1. Overview
7.3.3.2. Cholinesterase Inhibitors Market Forecast and Analysis
7.3.4. Monoclonal Antibodies Market
7.3.4.1. Overview
7.3.4.2. Monoclonal Antibodies Market Forecast and Analysis
7.3.5. Chronic Immunomodulators. Market
7.3.5.1. Overview
7.3.5.2. Chronic Immunomodulators. Market Forecast and Analysis
7.4. RAPID IMMUNOTHERAPIES
7.4.1. Overview
7.4.2. Rapid immunotherapies Market Forecast and Analysis
7.4.3. Plasmapheresis Market
7.4.3.1. Overview
7.4.3.2. Plasmapheresis Market Forecast and Analysis
7.4.4. Intravenous Immunoglobulin (IVlg) Market
7.4.4.1. Overview
7.4.4.2. Intravenous Immunoglobulin (IVlg) Market Forecast and Analysis
7.4.5. Thymectomy Market
7.4.5.1. Overview
7.4.5.2. Thymectomy Market Forecast and Analysis
8. MYASTHENIA GRAVIS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1 North America Myasthenia Gravis Market Overview
8.1.2 North America Myasthenia Gravis Market Forecasts and Analysis
8.1.3 North America Myasthenia Gravis Market Forecasts and Analysis - By Treatment
8.1.4 North America Myasthenia Gravis Market Forecasts and Analysis - By Countries
8.1.4.1 United States Myasthenia Gravis Market
8.1.4.1.1 United States Myasthenia Gravis Market by Treatment
8.1.4.2 Canada Myasthenia Gravis Market
8.1.4.2.1 Canada Myasthenia Gravis Market by Treatment
8.1.4.3 Mexico Myasthenia Gravis Market
8.1.4.3.1 Mexico Myasthenia Gravis Market by Treatment
8.2. EUROPE
8.2.1 Europe Myasthenia Gravis Market Overview
8.2.2 Europe Myasthenia Gravis Market Forecasts and Analysis
8.2.3 Europe Myasthenia Gravis Market Forecasts and Analysis - By Treatment
8.2.4 Europe Myasthenia Gravis Market Forecasts and Analysis - By Countries
8.2.4.1 Germany Myasthenia Gravis Market
8.2.4.1.1 Germany Myasthenia Gravis Market by Treatment
8.2.4.2 France Myasthenia Gravis Market
8.2.4.2.1 France Myasthenia Gravis Market by Treatment
8.2.4.3 Italy Myasthenia Gravis Market
8.2.4.3.1 Italy Myasthenia Gravis Market by Treatment
8.2.4.4 Spain Myasthenia Gravis Market
8.2.4.4.1 Spain Myasthenia Gravis Market by Treatment
8.2.4.5 United Kingdom Myasthenia Gravis Market
8.2.4.5.1 United Kingdom Myasthenia Gravis Market by Treatment
8.3. ASIA-PACIFIC
8.3.1 Asia-Pacific Myasthenia Gravis Market Overview
8.3.2 Asia-Pacific Myasthenia Gravis Market Forecasts and Analysis
8.3.3 Asia-Pacific Myasthenia Gravis Market Forecasts and Analysis - By Treatment
8.3.4 Asia-Pacific Myasthenia Gravis Market Forecasts and Analysis - By Countries
8.3.4.1 Australia Myasthenia Gravis Market
8.3.4.1.1 Australia Myasthenia Gravis Market by Treatment
8.3.4.2 China Myasthenia Gravis Market
8.3.4.2.1 China Myasthenia Gravis Market by Treatment
8.3.4.3 India Myasthenia Gravis Market
8.3.4.3.1 India Myasthenia Gravis Market by Treatment
8.3.4.4 Japan Myasthenia Gravis Market
8.3.4.4.1 Japan Myasthenia Gravis Market by Treatment
8.3.4.5 South Korea Myasthenia Gravis Market
8.3.4.5.1 South Korea Myasthenia Gravis Market by Treatment
8.4. MIDDLE EAST AND AFRICA
8.4.1 Middle East and Africa Myasthenia Gravis Market Overview
8.4.2 Middle East and Africa Myasthenia Gravis Market Forecasts and Analysis
8.4.3 Middle East and Africa Myasthenia Gravis Market Forecasts and Analysis - By Treatment
8.4.4 Middle East and Africa Myasthenia Gravis Market Forecasts and Analysis - By Countries
8.4.4.1 South Africa Myasthenia Gravis Market
8.4.4.1.1 South Africa Myasthenia Gravis Market by Treatment
8.4.4.2 Saudi Arabia Myasthenia Gravis Market
8.4.4.2.1 Saudi Arabia Myasthenia Gravis Market by Treatment
8.4.4.3 U.A.E Myasthenia Gravis Market
8.4.4.3.1 U.A.E Myasthenia Gravis Market by Treatment
8.5. SOUTH AND CENTRAL AMERICA
8.5.1 South and Central America Myasthenia Gravis Market Overview
8.5.2 South and Central America Myasthenia Gravis Market Forecasts and Analysis
8.5.3 South and Central America Myasthenia Gravis Market Forecasts and Analysis - By Treatment
8.5.4 South and Central America Myasthenia Gravis Market Forecasts and Analysis - By Countries
8.5.4.1 Brazil Myasthenia Gravis Market
8.5.4.1.1 Brazil Myasthenia Gravis Market by Treatment
8.5.4.2 Argentina Myasthenia Gravis Market
8.5.4.2.1 Argentina Myasthenia Gravis Market by Treatment
9. INDUSTRY LANDSCAPE
9.1. MERGERS AND ACQUISITIONS
9.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
9.3. NEW PRODUCT LAUNCHES
9.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
10. MYASTHENIA GRAVIS MARKET, KEY COMPANY PROFILES
10.1. NOVARTIS AG
10.1.1. Key Facts
10.1.2. Business Description
10.1.3. Products and Services
10.1.4. Financial Overview
10.1.5. SWOT Analysis
10.1.6. Key Developments
10.2. NIHON PHARMACEUTICAL CO., LTD
10.2.1. Key Facts
10.2.2. Business Description
10.2.3. Products and Services
10.2.4. Financial Overview
10.2.5. SWOT Analysis
10.2.6. Key Developments
10.3. GRIFOLS, S.A
10.3.1. Key Facts
10.3.2. Business Description
10.3.3. Products and Services
10.3.4. Financial Overview
10.3.5. SWOT Analysis
10.3.6. Key Developments
10.4. BAUSCH HEALTH
10.4.1. Key Facts
10.4.2. Business Description
10.4.3. Products and Services
10.4.4. Financial Overview
10.4.5. SWOT Analysis
10.4.6. Key Developments
10.5. ALEXION
10.5.1. Key Facts
10.5.2. Business Description
10.5.3. Products and Services
10.5.4. Financial Overview
10.5.5. SWOT Analysis
10.5.6. Key Developments
10.6. F. HOFFMANN-LA ROCHE LTD
10.6.1. Key Facts
10.6.2. Business Description
10.6.3. Products and Services
10.6.4. Financial Overview
10.6.5. SWOT Analysis
10.6.6. Key Developments
10.7. CURAVAC
10.7.1. Key Facts
10.7.2. Business Description
10.7.3. Products and Services
10.7.4. Financial Overview
10.7.5. SWOT Analysis
10.7.6. Key Developments
10.8. BRISTOL-MYERS SQUIBB COMPANY
10.8.1. Key Facts
10.8.2. Business Description
10.8.3. Products and Services
10.8.4. Financial Overview
10.8.5. SWOT Analysis
10.8.6. Key Developments
10.9. RA PHARMACEUTICALS, INC
10.9.1. Key Facts
10.9.2. Business Description
10.9.3. Products and Services
10.9.4. Financial Overview
10.9.5. SWOT Analysis
10.9.6. Key Developments
10.10. ARGENX
10.10.1. Key Facts
10.10.2. Business Description
10.10.3. Products and Services
10.10.4. Financial Overview
10.10.5. SWOT Analysis
10.10.6. Key Developments
11. APPENDIX
11.1. ABOUT THE INSIGHT PARTNERS
11.2. GLOSSARY OF TERMS
The List of Companies

- Novartis AG
- NIHON PHARMACEUTICAL CO. , LTD
- Grifols, S. A.
- Bausch Health
- Alexion
- F. Hoffmann-La Roche Ltd
- Curavac
- Bristol-Myers Squibb Company
- Ra Pharmaceuticals, Inc
- argenx
Select License Type
USD $3000
USD $4550
USD $6550
USD $8550

Free

20%

customization on Pre-Booking
Pre Book